If you have been reading about PT-141 code and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-10. Numbers and descriptions here follow the published literature rather than marketing material.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
| Property | Value | Notes |
|---|---|---|
| Primary target | MC4R | Highest reported functional activity |
| Peak plasma time | About 1 hour | Subcutaneous administration |
| Elimination half-life | A few hours | Active fragment may extend effect |
| Main clearance route | Proteolytic degradation | Not cytochrome-dependent |
| Typical assay | LC-MS/MS | Plasma quantification |
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Symptoms include feverishness, a general sense of malaise, and pain or swelling around the genitals or in the skin behind them. The infection progresses quickly and urgent medical attention is recommended. Empagliflozin can increase the risk of low blood sugar when it is used together with a sulfonylurea or insulin. When used by itself or in addition to metformin it does not appear to increase the risk of hypoglycemia.
== Method of transport == Hemolymph fills the whole interior (the hemocoel) of the animal's body and surrounds all cells. In the grasshopper, the closed portion of the system consists of tubular hearts and an aorta running along the dorsal side of the insect. The hearts pump hemolymph into the chambers — called sinuses — of the hemocoel where exchanges of materials take place. Coordinated movements of the body muscles gradually bring the hemolymph back to the dorsal sinus surrounding the hearts. Between contractions, tiny valves — called ostia — in the walls of the hearts open and allow hemolymph to enter. Hemolymph contains hemocyanin, a copper-based protein that turns blue when oxygenated, causing the hemolymph to turn from grey to blue-green in color. This contrasts with the iron-based hemoglobin found in the red blood cells of vertebrate blood which turns a brighter red when oxygenated. The hemolymph of lower arthropods, including most insects, contains nutrients such as proteins and sugars but is not used for oxygen transport. These animals respirate through other means, such as tracheas. Ancestral and functional hemocyanin has, however, been found in the hemolymph of some insects. Insect hemolymph generally does not carry hemoglobin, but hemoglobin may be present in the tracheal system and may play some role in respiration there. Muscular movements by the animal during locomotion can facilitate hemolymph movement, but diverting flow from one area to another is limited.
== Metabolism == Isoniazid reaches therapeutic concentrations in serum, cerebrospinal fluid, and within caseous granulomas. It is metabolized in the liver via acetylation into acetylhydrazine. Two forms of the enzyme are responsible for acetylation, so some patients metabolize the drug more quickly than others. Hence, the half-life is bimodal, with "slow acetylators" and "fast acetylators". A graph of number of people versus time shows peaks at one and three hours. The height of the peaks depends on the ethnicities of the people being tested. The metabolites are excreted in the urine. Doses do not usually have to be adjusted in case of renal failure.
Vitamin D is a group of structurally related, fat-soluble compounds responsible for increasing intestinal absorption of calcium, along with numerous other biological functions. In humans, the most important compounds within this group are vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol). Unlike the other twelve vitamins, vitamin D is only conditionally essential in the diet, as with adequate skin exposure to the ultraviolet B (UVB) radiation component of sunlight there is synthesis of cholecalciferol in the deeper layers of the skin's epidermis. Vitamin D can also be obtained through diet, food fortification and dietary supplements. For most people, skin synthesis contributes more than dietary sources. Accordingly, the name "vitamin D" is arguably a misnomer, as rather than being an essential part of the diet, it acts more like a fat-soluble secosteroid hormone precursor. Nevertheless, US and other dietary guidelines generally assume that all of a person's vitamin D is taken orally, given the potential for insufficient sunlight exposure due to urban living, cultural choices for the amount of clothing worn when outdoors, and use of sunscreen because of concerns about safe sunlight exposure. In many countries, milk and plant-based milk substitutes are fortified with vitamin D3, as are breakfast cereals. Cholecalciferol is converted in the liver to calcifediol (also known as calcidiol or 25-hydroxycholecalciferol), while ergocalciferol is converted to ercalcidiol (25-hydroxyergocalciferol).
Sources: en.wikipedia.org
== History == In the mid-1980s, McDonald's sought to introduce menu items positioned as fresher or lighter options to compete with the Whopper from rival chain Burger King. Reporting on the chain's expansion into fresh vegetables noted that McDonald's had historically resisted placing lettuce and tomato on burgers, fearing the hot meat would wilt the ingredients and make the bun soggy. McDonald's developed a dual-compartment sandwich package that physically separated the hot and cold components. The burger was invented by Wil May, a Lufkin, Texas franchisee. It rolled out nationwide in 1985 as the McDLT. McDonald's use of polystyrene foam packaging became a frequent target of environmental criticism during the late 1980s. Activists often cited the McDLT's large container as a symbol of excessive waste. In late 1990, amid growing public and regulatory pressure, McDonald's announced it would phase out foam packaging. The chain discontinued the McDLT in January 1991, replacing it with the McLean Deluxe, a lower-fat burger that did not use the dual-compartment packaging. McDonald's revisited the "hot and cold" concept in later years with the Big N' Tasty, though it was served in standard cardboard and paper packaging. In 2025, Al Roker said he wished McDonald's would bring back the McDLT.
==== Australia ==== DET is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.
Some spiders use their webs for hearing, where the giant webs function as extended and reconfigurable auditory sensors. Not all use their webs for capturing prey directly, instead pouncing from concealment (e.g. trapdoor spiders) or running them down in open chase (e.g. wolf spiders). The net-casting spider balances the two methods of running and web spinning in its feeding habits. This spider weaves a small net which it attaches to its front legs. It then lurks in wait for potential prey and, when such prey arrives, lunges forward to wrap its victim in the net, bite and paralyze it. Hence, this spider expends less energy catching prey than a primitive hunter such as the wolf spider. It also avoids the energy loss of weaving a large orb web. Many species also spin threads of silk to catch the wind and then sail on the wind to a new location. Others manage to use the signaling-snare technique of a web without spinning a web at all. Several types of water-dwelling spiders rest their feet on the water's surface in much the same manner as an orb-web user. When an insect falls onto the water and is ensnared by surface tension, the spider can detect the vibrations and run out to capture the prey. The diving bell spider and Desis marina, an intertidal species, use their web to trap air under water, where they can stay submerged long periods of time.
Sources: en.wikipedia.org
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.
Elimination is rapid, with a half-life of a few hours. An active fragment circulates after breakdown, so biological activity may outlast measurable parent drug. This is one reason single-timepoint measurements are limited.
Because breakdown is mainly proteolytic rather than cytochrome-dependent, classic metabolic interactions are less likely. Agents affecting blood pressure could still matter. Formal interaction studies are sparse.
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.